Squarepoint
SYRE icon

Squarepoint’s Spyre Therapeutics SYRE Stock Holding History

Squarepoint’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4M Buy
+139,605
New +$10.2M 0.01% 968
2025
Q4 		– Sell
-20,232
Closed -$339K – 4879
2025
Q3 		$339K Sell
20,232
-9,814
-33% -$160K ﹤0.01% 3572
2025
Q2 		$450K Sell
30,046
-41,965
-58% -$621K ﹤0.01% 3363
2025
Q1 		$1.16M Buy
72,011
+56,780
+373% +$1.18M ﹤0.01% 2528
2024
Q4 		$355K Buy
15,231
+6,754
+80% +$198K ﹤0.01% 4036
2024
Q3 		$249K Buy
+8,477
New +$236K ﹤0.01% 3568
2024
Q2 		– Sell
-8,161
Closed -$310K – 4635
2024
Q1 		$310K Buy
+8,161
New +$236K ﹤0.01% 3357
2020
Q4 		– Sell
-1,608
Closed -$285K – 3252
2020
Q3 		$285K Buy
1,608
+56
+4% +$10.4K ﹤0.01% 1837
2020
Q2 		$359K Buy
1,552
+601
+63% +$114K 0.01% 1492
2020
Q1 		$111K Sell
951
-978
-51% -$166K ﹤0.01% 1620
2019
Q4 		$368K Sell
1,929
-905
-32% -$178K ﹤0.01% 1931
2019
Q3 		$545K Buy
2,834
+719
+34% +$140K ﹤0.01% 1574
2019
Q2 		$362K Buy
2,115
+565
+36% +$97.7K ﹤0.01% 1845
2019
Q1 		$312K Sell
1,550
-828
-35% -$173K ﹤0.01% 1751
2018
Q4 		$445K Sell
2,378
-482
-17% -$102K 0.01% 1312
2018
Q3 		$684K Buy
2,860
+1,536
+116% +$359K 0.01% 1166
2018
Q2 		$350K Buy
1,324
+900
+212% +$221K ﹤0.01% 1323
2018
Q1 		$105K Buy
+424
New +$76.6K ﹤0.01% 1567
2017
Q2 		– Sell
-488
Closed -$91K – 1799
2017
Q1 		$91K Buy
+488
New +$68.9K ﹤0.01% 1424

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Squarepoint's SYRE Position: Q2 2026 in Review

Squarepoint opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 139,605 shares worth $12.4M. The stake represents 0.01% of the portfolio and ranks #968 among its holdings. This is a return to the name: Squarepoint previously reported a position in SYRE as recently as Q3 2025.

Squarepoint first reported a position in SYRE in Q1 2017 and has held it in 19 quarters since. 267 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Squarepoint held 139,605 shares of Spyre Therapeutics worth $12.4M as of Q2 2026.
  • Spyre Therapeutics was a new Squarepoint position in Q2 2026.
  • Spyre Therapeutics made up 0.01% of Squarepoint's portfolio in Q2 2026, its #968 holding.
  • Squarepoint first reported a position in Spyre Therapeutics in Q1 2017 and has held it in 19 quarters since.
  • 267 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.